HOME >> BIOLOGY >> NEWS
Malaria called failure, puzzle and challenge

Malaria, a tropical disease that has been called one of the most complex health problems facing humanity in the 20th century, is at once a failure, a puzzle, and a serious challenge, according to the Pan American Health Organization.

The latest issue of PAHO's Perspectives in Health magazine notes that the fight against malaria to date has been a failure because a worldwide eradication program that began in 1956 subsequently was abandoned, but only after the expenditure of millions of dollars and the efforts of thousands of health workers. Malaria remains a puzzle because researchers have not found a vaccine after 30 years of trying. And malaria presents a challenge because it still infects 300 million people a year in the world, kills over one million of these annually, and leaves millions more sick and debilitated.

Today malaria is transmitted actively in 21 countries and territories in the Western Hemisphere. But a new program, Roll Back Malaria seeks to cut deaths from malaria in half by the year 2010, according to Dr. Renato Gusmao, malaria expert for PAHO. The plan aims to reduce malaria incidence by controlling transmission, using community health workers to help diagnose and treat the disease.

PAHO Director Dr. George Alleyne says that "Despite earlier successes in shrinking the disease's geographical boundaries, malaria control today is more difficult than ever. Much of the increased risk is linked to changes in land use, such as road-building, mining, logging, agricultural and irrigation projects, particularly in frontier areas such as the Amazon."

In a column for the magazine, Dr. Alleyne notes that the Roll Back malaria initiative "proposes nothing less than a major assault on the disease, backed by a unified political commitment" that requires the contribution of "families; schools; businesses; the health, environmental, water supply and sanitation sectors" and all those whose activities directly or indirectly affect the m
'"/>

Contact: Daniel Epstein
epsteind@paho.org
202-974-3459
Pan American Health Organization
21-Jun-1999


Page: 1 2 3 4

Related biology news :

1. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
2. Malaria rise in Africa parallels warming trends
3. Pan-African Malaria Conference November 17-22 in Arusha, Tanzania
4. Multilateral Initiative on Malaria Secretariat to move to Sweden
5. Malaria research and training benefits global community
6. Multicomponent Malaria Vaccine Shows Promise in Laboratory Tests
7. Christmas Travellers Are Warned Of Malaria Risks
8. Genetic Code Of Chromosome Of Malaria Parasite Deciphered
9. Virginia Tech Scientist Seek Genetic Solution To Malaria
10. Severe Falciparum Malaria Increases In Honduras
11. Curing Malaria, Controlling Mosquitoes Symposium Set For AAAS Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Malaria called failure puzzle and challenge

(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:11/21/2014)... The report, "Synthetic Biology ... Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, ... Bioremediation) - Global Forecast to 2018", analyses ... opportunities, and challenges. , Browse 99 market ... 185 pages and in-depth TOC of the ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: